$2.59 Billion is the total value of Deep Track Capital, LP's 63 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 88.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ITCI | Buy | INTRA-CELLULAR THERAPIES INC | $135,434,000 | +38.1% | 2,600,000 | +67.9% | 5.23% | +15.2% |
| GH | Buy | GUARDANT HEALTH INC | $120,042,000 | +123.5% | 4,050,000 | +170.0% | 4.63% | +86.4% |
| ALKS | Buy | ALKERMES PLC | $106,438,000 | +13.4% | 3,800,000 | +26.7% | 4.11% | -5.5% |
| DVAX | Buy | DYNAVAX TECHNOLOGIES CORP | $99,800,240 | +17.8% | 6,756,956 | +3.0% | 3.85% | -1.8% |
| PLRX | Buy | PLIANT THERAPEUTICS INC | $95,370,000 | +30.0% | 5,500,000 | +35.8% | 3.68% | +8.4% |
| AXSM | Buy | AXSOME THERAPEUTICS INC | $79,726,668 | +188.8% | 1,140,745 | +196.9% | 3.08% | +140.8% |
| BCYC | Buy | BICYCLE THERAPEUTICS PLCsponsored ads | $70,124,266 | -2.5% | 3,490,506 | +23.8% | 2.71% | -18.7% |
| NTLA | Buy | INTELLIA THERAPEUTICS INC | $63,240,000 | +85.6% | 2,000,000 | +139.4% | 2.44% | +54.8% |
| EDIT | Buy | EDITAS MEDICINE INC | $55,395,093 | +94.9% | 7,101,935 | +105.6% | 2.14% | +62.5% |
| GERN | Buy | GERON CORP | $54,484,000 | -29.8% | 25,700,000 | +6.3% | 2.10% | -41.5% |
| New | APOGEE THERAPEUTICS INC | $51,426,145 | – | 2,414,373 | +100.0% | 1.98% | – | |
| PACB | Buy | PACIFIC BIOSCIENCES CALIF IN | $50,100,000 | +159.6% | 6,000,000 | +313.5% | 1.93% | +116.6% |
| VRDN | Buy | VIRIDIAN THERAPEUTICS INC | $45,456,516 | +49.3% | 2,963,267 | +131.6% | 1.76% | +24.6% |
| NVCR | New | NOVOCURE LTD | $40,375,000 | – | 2,500,000 | +100.0% | 1.56% | – |
| New | HILLEVAX INC | $39,005,000 | – | 2,900,000 | +100.0% | 1.51% | – | |
| RPTX | Buy | REPARE THERAPEUTICS INC | $37,058,190 | +28.4% | 3,067,731 | +12.5% | 1.43% | +7.0% |
| AGEN | Buy | AGENUS INC | $35,818,219 | -25.4% | 31,697,539 | +5.7% | 1.38% | -37.8% |
| NBIX | New | NEUROCRINE BIOSCIENCES INC | $33,750,000 | – | 300,000 | +100.0% | 1.30% | – |
| TERN | Buy | TERNS PHARMACEUTICALS INC | $30,180,000 | +213.8% | 6,000,000 | +445.9% | 1.16% | +161.8% |
| RAPT | Buy | RAPT THERAPEUTICS INC | $24,930,000 | +32.7% | 1,500,000 | +49.3% | 0.96% | +10.6% |
| ANAB | New | ANAPTYSBIO INC | $24,170,801 | – | 1,345,813 | +100.0% | 0.93% | – |
| OLMA | New | OLEMA PHARMACEUTICALS INC | $23,846,541 | – | 1,930,894 | +100.0% | 0.92% | – |
| New | AMYLYX PHARMACEUTICALS INC | $23,058,424 | – | 1,259,335 | +100.0% | 0.89% | – | |
| BNTX | New | BIONTECH SEsponsored ads | $21,728,000 | – | 200,000 | +100.0% | 0.84% | – |
| MRNA | New | MODERNA INC | $20,658,000 | – | 200,000 | +100.0% | 0.80% | – |
| New | ORCHARD THERAPEUTICS PLCspon ads new | $15,782,109 | – | 2,041,670 | +100.0% | 0.61% | – | |
| NKTR | Buy | NEKTAR THERAPEUTICS | $10,959,040 | +6.0% | 18,400,000 | +2.4% | 0.42% | -11.7% |
| MORF | Buy | MORPHIC HLDG INC | $10,782,523 | -13.2% | 470,647 | +117.1% | 0.42% | -27.7% |
| AGIO | New | AGIOS PHARMACEUTICALS INC | $10,450,613 | – | 422,247 | +100.0% | 0.40% | – |
| TXG | New | 10X GENOMICS INC | $7,536,004 | – | 182,691 | +100.0% | 0.29% | – |
| NVAX | New | NOVAVAX INC | $7,240,000 | – | 1,000,000 | +100.0% | 0.28% | – |
| New | ACELYRIN INC | $5,606,609 | – | 551,289 | +100.0% | 0.22% | – | |
| New | SYROS PHARMACEUTICALS INC | $3,272,516 | – | 828,485 | +100.0% | 0.13% | – | |
| SRRK | New | SCHOLAR ROCK HLDG CORP | $2,512,371 | – | 353,855 | +100.0% | 0.10% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| JAZZ PHARMACEUTICALS PLC | 8 | Q3 2023 | 7.2% |
| TRAVERE THERAPEUTICS INC | 8 | Q3 2023 | 5.7% |
| IMMUNOVANT INC | 8 | Q3 2023 | 7.2% |
| BICYCLE THERAPEUTICS PLC | 8 | Q3 2023 | 5.2% |
| BEAM THERAPEUTICS INC | 8 | Q3 2023 | 3.9% |
| 4D MOLECULAR THERAPEUTICS IN | 8 | Q3 2023 | 2.9% |
| REPARE THERAPEUTICS INC | 8 | Q3 2023 | 3.1% |
| VIRIDIAN THERAPEUTICS INC | 8 | Q3 2023 | 2.2% |
| DYNE THERAPEUTICS INC | 8 | Q3 2023 | 2.2% |
| SILENCE THERAPEUTICS PLC | 8 | Q3 2023 | 1.6% |
View Deep Track Capital, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Orchard Therapeutics plc | March 20, 2023 | 19,125,150 | 10.0% |
| ARDELYX, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2023 | 1,833,437 | 3.8% |
| Aurinia Pharmaceuticals Inc. | February 14, 2023 | 324,238 | 0.2% |
| CHINOOK THERAPEUTICS, INC. | February 14, 2023 | 3,000,000 | 4.7% |
| Forma Therapeutics Holdings, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Global Blood Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| HOOKIPA Pharma Inc. | February 14, 2023 | 1,240,369 | 2.4% |
| KalVista Pharmaceuticals, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Keros Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View Deep Track Capital, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-26 |
| SC 13G | 2024-04-26 |
| SC 13G/A | 2024-04-22 |
| SC 13G | 2024-04-12 |
| SC 13G | 2024-04-05 |
| SC 13G | 2024-03-22 |
| SC 13G | 2024-03-22 |
| SC 13G | 2024-03-22 |
| SC 13G | 2024-03-15 |
| 3 | 2024-03-14 |
View Deep Track Capital, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.